Indegene

Overview

Indegene is a digital-first life sciences commercialization company headquartered in Bangalore, India, with US operations based in Princeton, New Jersey. Founded in 1998, the company provides technology-enabled services across the biopharma value chain, from clinical and medical affairs to commercial operations. Indegene integrates deep healthcare domain expertise with proprietary AI platforms to help pharma, biotech, and medical device firms accelerate product development, market entry, and lifecycle management.

The company went public on India’s NSE/BSE exchanges in May 2024 in an IPO that was 70x oversubscribed, signaling strong market confidence. Trailing twelve-month revenue stands at approximately $400-420M, with Q3 FY26 revenue of $106M representing 30.8% year-over-year growth. Indegene has achieved a remarkable 10-year revenue CAGR of 28%, making it one of the fastest-growing companies in pharma services.

A distinguishing characteristic is Indegene’s delivery model: 82-84% offshore (primarily India), with 23-27% of headcount being healthcare-credentialed professionals (physicians, pharmacists, nurses) — an unusually high ratio for a tech-services firm that enables clinical-grade content production at offshore economics.

Services & Capabilities

Enterprise Commercial Solutions (~71% of revenue)

• Omnichannel marketing strategy and activation
• Digital HCP engagement and content production
• Commercial analytics and campaign optimization
• Exeevo CRM platform (proprietary, cloud-based)
• Brand launch support and lifecycle management
• Creative services and digital asset production

Enterprise Medical Solutions (~25% of revenue, fastest growing)

• NEXT Medical Writing platform (AI-accelerated regulatory writing)
• Pharmacovigilance and safety case processing
• Real-world evidence analytics
• Regulatory submissions and compliance support
• Medical affairs and scientific communications
• Clinical trial recruitment support

Technology Platforms

• Cortex GenAI Platform: LLM-agnostic, multi-agent AI system for automating pharma workflows across content generation, medical review, analytics, and compliance
• Exeevo CRM: Cloud-native CRM purpose-built for life sciences
• NEXT: AI-powered medical writing and regulatory document automation

Competitive Position

Indegene competes at the intersection of pharma consulting, technology services, and agency work, leveraging its offshore delivery model to undercut Western competitors on cost while maintaining quality through its credentialed workforce.

Key competitors:

• Commercial technology: Veeva Systems, IQVIA (OCE), Salesforce Health Cloud
• Agency/services: Klick Health, Accenture Life Sciences, Cognizant
• Medical writing/regulatory: Clarivate, PAREXEL, Covance

Strengths:

• 10-year 28% CAGR demonstrates exceptional growth execution
• Offshore delivery model provides 30-50% cost advantage vs. Western peers
• 20 of top 20 pharma as clients (64% of revenue from top 20)
• Cortex GenAI platform positions for AI-native workflow transformation
• Healthcare-credentialed workforce (23-27%) enables clinical-grade output

Weaknesses:

• Client concentration: top client ~$47-50M (12% of revenue)
• Margin compression: operating margins declined from 22-23% to 18.5% due to M&A integration costs
• PAT (profit after tax) declined 6.2% despite 31% revenue growth — acquisition dilution
• Employee attrition at 15-17%, elevated for the sector
• Scale ceiling question: can the model scale from $400M to $1B without structural changes?

Recent Developments

• May 2024: IPO on India’s NSE/BSE exchanges; 70x oversubscribed. Carlyle and Brighton Park Capital retain minority stakes.
• October 2025: Acquired BioPharm Communications for $106M, adding AdTech and digital advertising capabilities for life sciences
• February 2026: Acquired Cake Health, a Vienna-based DACH healthcare agency, expanding European footprint
• 2025: Multiple UK acquisitions including MJL Communications and DT Associates/Trilogy Writing (£2.7M) for consulting and medical writing
• 2025: Launched Cortex GenAI platform; new centers in Hyderabad and London; established entity in Spain
• 2025: Carlyle completed full exit via ₹1,447 Cr stake sale on public markets

Client & Partner Ecosystem

• Scale: 86 active clients; 52 clients generating >$1M annually
• Top 20 penetration: 20 of top 20 biopharma companies as clients, accounting for 64% of revenue
• Named clients: Pfizer, Amgen, Johnson & Johnson, Boehringer Ingelheim (from public disclosures)
• Top client concentration: ~$47-50M from largest client (12% of total revenue)
• Partners: Datavant (data partnership), Acquia (content platform)

Technology Platform

Platform	Function	Differentiation
Cortex	GenAI platform for pharma workflow automation	LLM-agnostic, multi-agent architecture; works across content, compliance, analytics
Exeevo	Cloud-native CRM for life sciences	Purpose-built for pharma HCP engagement; competitor to Veeva CRM
NEXT	AI-powered medical writing	Accelerates regulatory document production; integrates with pharmacovigilance workflows

Therapeutic Focus

Broad coverage across all major therapeutic areas. No specific therapeutic specialization disclosed — the company positions as a horizontal platform serving all pharma verticals.

ZoomInfo](https://www.zoominfo.com/c/indegene/141361912)

• Medidata
• raw/research/indegene.pplx.md